Back to top

Analyst Blog

Pharmacyclics Inc. (PCYC - Analyst Report) received encouraging news when the U.S. Food and Drug Administration (FDA) approved its oncology drug Imbruvica (ibrutinib).The U.S. regulatory body cleared the drug as a monotherapy for treating patients suffering from mantle cell lymphoma (MCL). The patients were treated at least once previously for the disease. Pharmacyclics has co-developed the drug with Janssen Biotech, a Johnson & Johnson (JNJ - Analyst Report) company.

The FDA decision marks the first approval for Pharmacyclics. Investors reacted positively to the news. We note that the FDA reviewed Pharmacyclics’ new drug application seeking marketing approval for Imbruvica for the indication on a priority basis. The NDA was submitted to the FDA in Jun 2013.

The FDA had granted breakthrough therapy designation to the drug for the indication earlier in the year. Pharmacyclics stated in its press release that Imbruvica is one of the first drugs to gain approval from the U.S. regulatory body via the breakthrough therapy designation route. Pharmacyclics is also seeking U.S. approval of the drug for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

The FDA cleared Imbruvica for the MCL indication on the basis of encouraging data pertaining to overall response rate from a multi-center, international, single-arm study (n=111). The drug is recommended to be taken once daily (4 pills 140 mg each). The drug will cost $10,900 a month. Imbruvica will compete with drugs like Celgene Corporation’s (CELG - Analyst Report) Revlimid in the MCL market.

Successful commercialization of Imbruvica in the MCL indication would bring in substantial revenues to Pharmacyclics. The drug is being developed to treat other cancer forms as well.

Pharmacyclics, a biopharmaceutical company, carries a Zacks Rank #2 (Buy). Actelion Ltd. (ALIOF) appears to be more attractive in the biopharma space with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%